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Available online 16 February 2017Since the 1980s, titanium (Ti) implants have been routinely used to replace missing teeth. This success is mainly
due to the good biocompatibility of Ti and the phenomenon of osseointegration,with very early events at implant
placement being important in determining good osseointegration. However, enhancing implant performance
with coatings such as hydroxyapatite (HA) and calcium phosphate has proved largely unsuccessful. Humanmes-
enchymal stem cells (hMSCs) are the ﬁrst osteogenic cells to colonise implant surfaces and offer a target for en-
hancing osseointegration. We previously reported that small doses of bisphosphonate (BP) may play an integral
role in enhancing hMSC proliferation and osteogenic differentiation. The aimof this study is to investigatewheth-
er small doses of bisphosphonates enhance proliferation and osteogenic differentiation of hMSCs on Ti surfaces,
to enhance bone osseointegration and to acceleratewoundhealing around the implant surface. Our data suggests
that treating cells with small doses of BP (100 nM & 10 nM) induces signiﬁcant hMSC stimulation of osteogenic
markers including calcium, collagen type I and ALP compared to control group on titanium surfaces (P b 0.05). In
addition, cell proliferation and migration were signiﬁcantly enhanced on titanium surfaces (P b 0.05).
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Titanium1. Introduction
In recent decades, titanium (Ti) implants have been successfully
used to replacemissing teeth. This success ismainly due to the good bio-
compatibility of Ti and the phenomenon of osseointegration. Following
implantation, the surrounding tissue may respond in two ways; forma-
tion of ﬁbrous tissue or formation of new bone. Formation of ﬁbrous tis-
sue around the implant will lead to the clinical failure of the implant,
whereas formation of new bone on the implant surface without inter-
fering connective tissue is the desired outcome (Baas et al., 2012). The
surface properties of the implant play an integral role for implant
osseointegration (Le et al., 2007, Colombo et al., 2012). Also, the topog-
raphy and chemistry of the surface properties can control the quantity
and quality of adhered cells to the implant (Rosales-Leal et al., 2010,
Logan and Brett, 2013). It has been reported that optimal surface rough-
ness can lead to effective osseointegration (Halldin et al., 2014). This ef-
fect was due to increased osteoblast proliferation, differentiation and
matrix protein production, e.g. collagen type I. Furthermore, surface hy-
drophilicity enhances cell interaction and adhesion to dental implants
(Zhao et al., 2005, Logan et al., 2014a).University College London, 256
. This is an open access article underThe coating of metal dental implants with different bone inducing
materials can induce positive effects. These materials include, bone
stimulating factors, bisphosphonates, ﬂuoride, HA and calcium phos-
phate, and titanium/titanium oxide (Logan et al., 2014b, Xuereb et al.,
2015). Calcium phosphate (CaP)which ismainly composed of hydroxy-
apatite has been shown to induce osteogenic differentiation and osteo-
blasts growth on implant surfaces (Yang, 2001). It has been reported
that coating implants with growth factors such as bone morphogenetic
protein (BMP) stimulates bone formation and improves implant success
(Wikesjo et al., 2008). HA also accelerates new bone formation by acti-
vation of osteoblast proliferation and differentiation (Kweon et al.,
2014, Lee et al., 2014, Yang et al., 2010). However, the long-term surviv-
al of HA-coated dental implants is still a controversial clinical issue. Plas-
ma spraying is a commonly used technique to coat implants, but this
technique has the disadvantage of requiring substantially thick coating
layers and furthermore, controlling the ﬁnal coating composition is dif-
ﬁcult. However, titanium implants are widely used in the clinic because
of their strength, low stiffness and light weight.
Bisphosphonates are chemical analogues related to pyrophosphate;
they are well-known inhibitors of osteoclast activity. Over the last
40 years, they been used in the clinic to treat various bone diseases
characterised by excessive bone resorption such as osteoporosis, malig-
nant bone disease and hypercalcaemia ofmalignancy (Dominguez et al.,
2011, Russell, 2011, Russell et al., 2007). Osteoporosis is one of themost
common skeletal diseases affecting the quality of all bones, includingthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Surface roughness and contact angle of Ti surface.
Mean ±Standard deviation
Surface roughness 0.63 μm ±0.004 μm
Contact angle 69.1° ±3.7°
65N.R. Alqhtani et al. / Bone Reports 6 (2017) 64–69the jaw(Berruti et al., 2001). Human mesenchymal stem cells (hMSCs)
show regenerative properties and are able to differentiate into different
cell types such as osteoblasts (Kobolak et al., 2015). We have shown
that various types of bisphosphonates promote osteogenic differentiation
of hMSCs in vitro (Alqhtani et al., 2014). These ﬁndings suggest that
bisphosphonatesmayhave adirect stimulus onosteoblastmineralisation.
It has also been reported that coating implantswith bisphosphonate-elut-
ing ﬁbrinogenmay improve implant osseointegration, but there are risks
in developing chronic osteomyelitis (Abtahi et al., 2012).
To our knowledge, the systemic application of low doses (less than
1000th of clinical doses) of bisphosphonate has not been tested on
hMSC proliferation and osteogenic differentiation on titanium implants.
With this in mind, the aim of this study was to investigate whether low
doses of bisphosphonate enhanced proliferation and osteogenic differ-
entiation of hMSCs on Ti surfaces. Furthermore, we investigated wheth-
er application of these bisphosphonates (pamidronate and alendronate)
enhanced bonequality, improved implant osseointegration and acceler-
ated wound healing around the surface of the implant. We investigated
the effect of these drugs on cell proliferation, migration, adhesion and
attachment. Osteogenic differentiation markers were measured includ-
ing calcium, collagen type I and alkaline phosphates activity (ALP).2. Materials and methods
2.1. Titanium discs preparation
Two commonly used bisphosphonates were assessed; alendronate
(ALE) and pamidronate (PAM) (Sigma-Aldrich) on hMSC proliferation
and osteogenic response to Ti surfaces. 15 mm diameter polished
titanium discs were used and were designed to ﬁt into the wells of 24
well tissue culture plates (Sarstedt). Surface roughness was analysed
using laser proﬁlometry (Scranton, Proscan 1000). Contact angleFig. 1. The effects of low doses of ALE and PAM (100 nM and 10 nM) on hMSC proliferation on T
and 10 nM) had shown signiﬁcant cell proliferationwhen compared to the control group thatw
signiﬁcant cell proliferation compared to the control group that treated with GM only on day 1measurements were performed using an optical contact angle meter
(KSV Instruments Ltd., CAM200).
2.2. Cell culture
hMSCs were cultured in 150 cm2 tissue culture ﬂasks (Sarstedt) in
minimum essential medium (α-MEM, Gibco BRL) supplemented with
10% foetal bovine serum (FBS) (Invitrogen) and 100 U/ml of penicillin/
streptomycin (P/S) (Sigma-Aldrich). hMSCs were incubated at 37 °C at
5% CO2 and harvested for experiments once they reached 80% conﬂuence.
To promote hMSCs osteogenic differentiation, osteogenic media (OM)
comprising of Dulbecco's modiﬁed Eagle's medium (DMEM) low glucose
pyruvate (Gibco), 10% foetal bovine serum, 100U/ml P/S, and further sup-
plemented with β-glycerol phosphate (Sigma-Aldrich), ascorbic acid
(Sigma-Aldrich), and dexamethasone (Sigma-Aldrich) was used.
2.3. Proliferation
hMSCswere seeded at a density of 1 ×104 cells/well in 1.9-cm2wells
containing growth media and incubated at 37 °C at 5% CO2. The next
day, the media was removed and changed to growth (GM) media and
media supplemented with different concentrations of alendronate and
pamidronate (100 nM & 10 nM). Proliferation of cells was assessed
using the Alamar blue assay (AbD Serotec). A 10% dye solution was
added to each well and cells incubated for 4 h at 37 °C at 5% CO2.
100 μl aliquots were transferred into 96 well black plates (Fisher Scien-
tiﬁc) to measure ﬂuorescence intensity (Excitation λ= 530 nm, emis-
sion λ= 590 nm) using a plate reader (BioTeK FLX800). Interpolation
with a standard plate was used to generate the cell numbers.
2.4. Cell migration
Cellmigration assays (Cultrex, 3465-.24-k)were used according to the
manufacturer's instructions to assess themigration of cells towards Ti sur-
faces in the presence of BPs. Brieﬂy, hMSCs were cultured in serum free
media 24 h prior to the assay. The next day, 10 × 104 cells per well
(n = 3) were seeded onto an 8 μm pore polymer membrane in an insert
chamber to facilitate cell migration. A 500 μl aliquot of GMwas placed at
the bottomof the chamber and cells incubated at 37 °C at 5% CO2 for 4.5 h.
Membranes were washed three times with wash buffer and incubatedi surfaces were assessed at different time points. (A): All groups treatedwith ALE (100 nM
as treatedwith GMonly on day 1, 3, 7 and 14. (B): The group treatedwith 100 nM showed
, 3, 7 and 14 (values = mean ± SD; P b 0.05).
Fig. 2. Signiﬁcant hMSC migration was observed after 4.5 h incubation at 37 °C at 5% CO2.
Signiﬁcant differenceswere observed between the cells treatedwith the lowdose of drugs
and control group (OM only). Each column represents the mean ± SD.
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Then the ﬂuorescence intensity (Excitation λ= 530 nm, emission λ=
590 nm) was measured on a plate reader (BioTeK FLX800). Interpolation
with a standard plate was used to generate the cell numbers.
2.5. Calcium deposition
The quantichrom calcium kit (BioAssay Systems) was used accord-
ing to manufacture instructions. Brieﬂy, cell monolayers were washed
with PBS then lysed with 500 μl 1 M HCl for ≤1 h after which 5 μl of ly-
sate was transferred to a clear bottomed 96-well plate. To this, 200 μl of
freshly preparedworking reagentwas added. Absorbanceswere read at
612 nm using a plate reader (Tecan, M200).
2.6. Extracellular collagen deposition
Collagen deposition was assayed using the Sirocel kit according to
manufacturer's instructions (Biocolor). Brieﬂy, cell monolayers wereFig. 3. Cells were divided into ﬁve groups with each group treated with different ALE and PAM
results showed that BPs signiﬁcantly stimulated hMSC mineralisation following drug treatmen
extracellular collagen formationwas analysed. The results showed that PAMsigniﬁcantly stimul
to cells that had been treated with OM only. No signiﬁcant changes were observed in cells trea
signiﬁcantly increased in all cells treated with the lower dose of BPs drug when compared to tlysed with cold 0.5 M acetic acid supplemented with 100 μg/ml porcine
pepsin. Samples were incubated overnight with 200 μl isolation and
concentration reagent at 4 °C. Concentrated samples were centrifuged
at 12,000 revolutions per minute (rpm) for 10 min to pellet collagen.
Pellets were stained with Sirius Red stain for 30 min, and then centri-
fuged at 12,000 rpm for 10min. The pellets werewashed in acid-salt so-
lution to remove excess dye. The stain was eluted in 250 μl alkali
solution. Absorbances were measured at 555 nm using a plate reader
(Tecan, M200).
2.7. Alkaline phosphatase activity
ALP activity was assessed using the colorimetric SensoLyte® pNPP
ALP Assay Kit (Cambridge Bioscience) according to the manufacturer's
instructions. Brieﬂy, 1 × 104 cells/well were seeded into 24-well plates
and grown for 24 h at 37 °C at 5% CO2. The media was changed to OM
supplemented with different concentrations (100 nM & 10 nM) of the
drug (ALE and PAM). At day 7, the cells were washed twice in PBS,
lysed with 500 μl 0.1% triton X-100, scraped into microcentrifuge
tubes and incubated at 4 °C for 10 min. The cell suspension was centri-
fuged at 2500 ×g for 10 min at 4 °C. For enzyme activity, the standards
and cell lysateswere incubated at 37 °C for 1 h, and then transferred to a
96-well plate and absorbances read at 405 nm using a plate reader
(Tecan, M200).
2.8. Immunocytochemistry and cell morphology
To analyse the effects of low BP doses (100 nM& 10 nM) on cell ad-
hesion and attachment, focal adhesion and cytoskeletal proteins, vincu-
lin and F-actin were studied using ﬂuorescence microscopy. Cells were
grown in 24 well plates and incubated with ALE and PAM in OM for
24 h. The next day, the medium was discarded, the cells washed with
PBS and ﬁxed with 4% paraformaldehyde for 30 min. Vinculin and f-
actin were permeabilise using triton ×100. The cells were rinsed with
PBS, blocked with 10% goat serum in PBS for 30 min at room tempera-
ture, and incubated with anti-vinculin antibody (Abcam) at 1:200 dilu-
tion and left at 4 °C overnight. Next day, after several PBS washes, the
cells were incubated with goat anti-mouse IgG 568 (Life Technologies)
at 1:200 dilution for 1 h at room temperature in the dark. The cells
were washed three times in PBS (5 min each) and stained with 4′,6-concentration (100 nM and 10 nM). (A): At day 21, calcium deposition was analysed. The
t for 21 days when compared to cells that had been treated with OM only. (B): At day 14,
atedhMSC to produce collagen following treatmentwith drugs for 14dayswhen compared
ted with ALE when compared to the control. (C): ALP activity after 7 days incubation was
he control group treated with OM only. Each column represents the mean ± SD.
Fig. 4. Actin and vinculin expression analysis after 24 h of culture in OMwith and without BPs. Groups that been treated with low dose of ALE and PAM showed a signiﬁcant increase in
actin and vinculin expression compared to the control group that was treated with only OM. Each column represents the mean ± SD.
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MSCs were stained with phalloidin-iFlour 488 in PBS (Abcam, 1:1000).
Finally, the cells were washed and viewed using a Leica – DMIRB ﬂuo-
rescence microscope equipped with COOLSNAP Monochrome Camera.
Images were collected and processed with ImageJ software and quanti-
ﬁable analysis performed using the same software.
2.9. Scanning electron microscopy
Scanning electron microscopy (SEM) was used to analyse cell mor-
phology. Cells were washed three times in cold PBS and ﬁxed in 3% glu-
taraldehyde in 0.1 M cacodylate buffer for 24 h at 4 °C. The next day,
ﬁxative was removed and the cells dehydrated in a series of graded
ethyl alcohols for 10 min at each concentration, and ﬁnally dried with
hexamethyldisilazane for 2 to 5 min with subsequent removal and dry-
ing for at least an hour. The dried samplesweremounted on stubs, coat-
ed with gold, and viewed using a FEI XL30 FEGSEM (FEI UK, UK).Fig. 5. Fluorescencemicroscopy images showing the effect of lowdose of drugs on cell organisati
abundant in cells treatedwith the ALE and PAM (100 nMand 10 nM). Likewise, vinculin express
objective. Scale bar = 50 μM. SEM images were found to correlate with ﬂuorescent images.2.10. Statistical analysis
hMSCs from three donors (N = 3) were used in triplicate (n = 3).
Surface roughness analysis were performed at n = 5, contact angle
measurement was performed at n = 9. Statistical analysis was carried
out using one-way analysis of variance (ANOVA) followed by a
Bonferroni post-test, with P b 0.05 considered to be statistically
signiﬁcant.3. Results
3.1. Surface properties
As shown in Table 1, surface roughness were analysed where the
mean of Ra value = 0.63 μm (n = 5) and the contact angle were per-
formed with a mean of 69.1 (n = 9).on and spreading on Ti surfaces after 24 h. Actin expression (green images) appearedmore
ion (red images) appearedmore abundant in treated cells. Imageswere taken using a ×40
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Human MSC proliferation in GM was examined over 1, 3, 7 and
14 days. ALE (100 nM and 10 nM) stimulated signiﬁcant cell prolifera-
tion in all cells on days 1, 3, 7 and 14 (Fig. 1(A)). Also, cells that had
been treated with 100 nM PAM showed signiﬁcant proliferation when
compared to control cells whichwere treated with GM only. Cells treat-
ed with 10 nM PAM promoted cell proliferation but it was not statisti-
cally signiﬁcant (Fig. 1(B)).
3.3. Migration
Cells after 4.5 h at 37 °C at 5% CO2, were observed to have migrated
towards the substrate. However, cells with low doses of BPs (100 nM
and 10nM) have shown that these drugs signiﬁcantly enhanced cellmi-
gration towards titanium surface when compared to the control group
that had been treated with OM only (Fig. 2).
3.4. Mineralisation
Markers that were linked to early and late stage osteogenesis were
analysed. These markers included calcium, collagen type I and ALP.
Data showed that both BP drugs signiﬁcantly stimulated hMSC osteo-
genesis following drug treatment for 3 weeks when compared to cells
that had been treated with OM only (Fig. 3(A) and (B)). However,
there was no signiﬁcant difference in collagen deposition for cells that
had been treated with ALE (Fig. 3(B)). Furthermore, ALP is a useful
early marker in osteogenesis and is believed to be part of the
mineralisation process. Data showed that treating hMSCs with ALE
and PAM for 7 days caused signiﬁcant increases in ALP activity (Fig.
3(C)).
3.5. Immunocytochemistry and cell morphology
Cell morphology was analysed by labelling cells with phalloidin to
visualise internal F-actin structures. Data showed that after 24 h of cul-
ture, those cells treated with ALN and PAM, exhibited clear differences
in cell appearance and spread. These ﬁnding were supported by SEM
images (Figs.s 4 and 5).
4. Discussion
Bone remodelling is a complex process requiring several cellular
processes; bone cell recruitment, differentiation, bone synthesis and an-
giogenesis to stimulate blood ﬂow (Seeman, 2009). Good biocompati-
bility and rapid osseointegration are essential elements of implant
success and stability (Goriainov et al., 2014, Plecko et al., 2012,
Quirynen et al., 2014, von et al., 2014). In this study, we investigated
whether low doses of BPs enhanced proliferation and osteogenic differ-
entiation of hMSCs on Ti surfaces. hMSCs were used as they are the ﬁrst
cells to colonise implant surfaces and offer a target for enhancing
osseointegration (Davies, 2003).
Topographical and chemical modiﬁcations of implant materials play
integral roles in cellular migration, attachment, adhesion and prolifera-
tion of hMSCs (Logan et al., 2015, Wall et al., 2009, Wang et al., 2008).
The ability of BPs to promote hMSCs proliferation on Ti surfaces is a cru-
cial factor in implant success. In this study, we observed that over time,
low doses of BP increased cell density at Ti surfaces. This observation
may inﬂuence bone formation and improve osseointegration. In addi-
tion, these ﬁndings suggest that ALE and PAM exert effects on stem
cell density. Furthermore, BPs appear to have a signiﬁcant impact on
hMSCs migration towards Ti surfaces. This effect may not be solely
due to cell proliferation, as our data indicates that BPs have an effect
at the cellular level by accelerating cell migration towards Ti surfaces.
These results are supported by enhanced adhesion and cell spreading
(Figs.s 4 & 5).SEM images showed that the ALE and PAM exerted effects on hMSC
morphology; cellswere spread and adhered to Ti surfaces. Thiswas con-
ﬁrmed by the expression of focal adhesion proteins; vinculin spreading
is considered a parameter of the interaction between the cell and im-
plant material (Ezzell et al., 1997, Logan and Brett, 2013). A ﬁrm attach-
ment and spread of hMSCs is an important factor for differentiation to
osteoblasts, which over time become mature and produce ﬁbronectin
(Terheyden et al., 2012). From these ﬁndings, we believe that the ALE
and PAM may have stimulatory effect on chemotactic behaviour to-
wards substrates such as Ti.
To evaluate BPs on hMSC mineralisation, both early and late osteo-
genic markers such as calcium, collagen type I and ALP activity were
assessed. It has been shown that in a clinical setting, following implan-
tation, several cell types migrate towards the implant surface including
endothelial cells, osteoblasts and stem cells (Khalil et al., 2011). This is a
very important step for osteoinduction and over time, this accumulation
at the implant surface will enhance implant stability and its success
(Javed et al., 2013, Truhlar et al., 2000).
Our data have shown that BPs exert stimulatory effects on hMSC os-
teogenic differentiation; cells treated with drugs produce more calcium
when compared to the control group. These results were supported by
elevation of ALP activity for both drugs after 7 days in culture. However,
collagen type I is themain component of the extracellular matrix and is
produced by osteoblasts and other cells derived from hMSCs (Gelse et
al., 2003). In this work, PAM stimulated higher collagen type I formation
on Ti surface compared to ALE; this could be that PAM is clinically more
potent thanALE. The clinical success of any implant is based on its ability
to anchor the endosseous implant to the surrounding bone (Chrcanovic
et al., 2015).
This research conﬁrms that low concentrations of ALE and PAM en-
hance the hMSC osteogenic response in vitro, and therefore could have
translational applications in vivo; enhancing osseointegration and clini-
cal outcomes for Ti and other bone implants. We found that systemic
application of low drug doses, which is critically, almost 1000 times
less than clinical doses and coating concentrations, has a largely beneﬁ-
cial effect on hMSC proliferation and osteogenic differentiation on Ti
surfaces. Previous reports have shown that coating with BPs inhibits
the osteolysis process (Abtahi et al., 2012, Stadelmann et al., 2008). In
contrast to these reports, in our study, we have assessed hMSC migra-
tion, proliferation and osteogenic differentiation and used recognised
assays and biomarkers to explore this phenomenon.
Apart from BP, different materials have also been used to stimulate
bone regeneration and formation such as guided bone regeneration
(GBR) (Donos et al., 2004, Elgali et al., 2015). Systemic application of
this drug in conjunction with regenerative materials such as the GBR
may synergistically enhance the bone remodelling process and acceler-
ate wound healing. These ﬁndings may enhance bone remodelling and
wound healing in the peri-implant area.
In conclusion,we have demonstrated that lowdoses of BPs stimulate
hMSCs proliferation and osteogenic differentiation on Ti surfaces. These
ﬁndings have promising implications in the systemic application of low
doses of these BP drugs towards improved implant osseointegration
and successful clinical outcomes. We believe that the systemic applica-
tion of BP drugs could be pivotal in accelerating osseointegration and
the bone healing process.
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